CM
KRYS icon

Castleark Management’s Krystal Biotech KRYS Stock Holding History

Castleark Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.17M Buy
31,630
+2,370
+8% +$631K 0.27% 87
2025
Q4 		$7.21M Buy
+29,260
New +$6.16M 0.21% 114
2025
Q2 		– Sell
-26,120
Closed -$4.71M – 310
2025
Q1 		$4.71M Buy
+26,120
New +$4.39M 0.16% 129
2024
Q4 		– Sell
-27,290
Closed -$4.97M – 308
2024
Q3 		$4.97M Sell
27,290
-990
-4% -$191K 0.2% 123
2024
Q2 		$5.19M Sell
28,280
-240
-0.8% -$40.3K 0.21% 111
2024
Q1 		$5.07M Sell
28,520
-3,830
-12% -$532K 0.21% 116
2023
Q4 		$4.01M Buy
32,350
+20,930
+183% +$2.32M 0.18% 136
2023
Q3 		$1.32M Buy
+11,420
New +$1.39M 0.07% 181

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return